

NCT00989261 Raw comparison:

Summary:
CHIA has 36 criteria while your personal folder has 41 criteria
Total found criteria: 33/36
Total not Found: 3/36
Total Extra: 5
This trial is INVALID



╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╕
│ CHIA Criteria                                      │ Matching Personal Criteria                         │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╡
│ Males and females age ≥18 years in second relapse  │ Males and females age ≥18 years in second relapse  │
│ or refractory                                      │ or refractory                                      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Males and females age ≥60 years in first relapse   │ Males and females age ≥60 years in first relapse   │
│ or refractory                                      │ or refractory                                      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Must have baseline bone marrow sample taken        │ Must have baseline bone marrow sample taken        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Morphologically documented primary AML or AML      │ Morphologically documented primary AML or AML      │
│ secondary to myelodysplastic syndrome (MDS with    │ secondary to myelodysplastic syndrome (MDS with    │
│ ≥20% bone marrow or peripheral blasts) as defined  │ ≥20% bone marrow or peripheral blasts) as defined  │
│ by the World Health Organization (WHO) criteria    │ by the World Health Organization (WHO) criteria    │
│ confirmed by pathology review at treating          │ confirmed by pathology review at treating          │
│ institution                                        │ institution                                        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Able to swallow the liquid study drug              │ Able to swallow the liquid study drug              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ In the absence of rapidly progressing disease the  │ In the absence of rapidly progressing disease the  │
│ interval from prior treatment to time of AC220     │ interval from prior treatment to time of AC220     │
│ administration will be at least 2 weeks for        │ administration will be at least 2 weeks for        │
│ cytotoxic agents or at least 5 half-lives for      │ cytotoxic agents or at least 5 half-lives for      │
│ noncytotoxic agents The use of chemotherapeutic or │ noncytotoxic agents The use of chemotherapeutic or │
│ antileukemic agents other than hydroxyurea is not  │ antileukemic agents other than hydroxyurea is not  │
│ permitted during the study with the possible       │ permitted during the study with the possible       │
│ exception of intrathecal (IT) therapy at the       │ exception of intrathecal (IT) therapy at the       │
│ discretion of the Investigator and with the        │ discretion of the Investigator and with the        │
│ agreement of the Sponsor                           │ agreement of the Sponsor                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Persistent chronic clinically significant non-     │ Persistent chronic clinically significant non-     │
│ hematological toxicities from prior treatment must │ hematological toxicities from prior treatment must │
│ be ≤Grade 1                                        │ be ≤Grade 1                                        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Prior therapy with FLT3 inhibitors is permitted    │ Prior therapy with FLT3 inhibitors is permitted    │
│ except previous treatment with AC220               │ except previous treatment with AC220               │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Serum potassium magnesium and calcium levels       │ Serum potassium magnesium and calcium levels       │
│ should be at least within institutional normal     │ should be at least within institutional normal     │
│ limits                                             │ limits                                             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Total serum bilirubin ≤1 5 × ULN                   │ Total serum bilirubin ≤1 5 × ULN                   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Serum aspartate transaminase (AST) and/or alanine  │ Serum aspartate transaminase (AST) and/or alanine  │
│ transaminase (ALT) ≤2 5 × ULN                      │ transaminase (ALT) ≤2 5 × ULN                      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Females of childbearing potential must have a      │ Females of childbearing potential must have a      │
│ negative pregnancy test (urine β-hCG)              │ negative pregnancy test (urine β-hCG)              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Females of childbearing potential and sexually     │ Females of childbearing potential and sexually     │
│ mature males must agree to use a medically         │ mature males must agree to use a medically         │
│ accepted method of contraception throughout the    │ accepted method of contraception throughout the    │
│ study                                              │ study                                              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Written informed consent must be provided          │ Written informed consent must be provided          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Patients over the age of 85 years except at the    │ Patients over the age of 85 years except at the    │
│ discretion of the Investigator and with agreement  │ discretion of the Investigator and with agreement  │
│ of the Sponsor                                     │ of the Sponsor                                     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Diagnosis of acute promyelocytic leukemia          │ Diagnosis of acute promyelocytic leukemia          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Diagnosis of chronic myelogenous leukemia (CML) in │ Diagnosis of chronic myelogenous leukemia (CML) in │
│ blast crisis                                       │ blast crisis                                       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ AML in relapse or refractory after 3 or more       │ AML in relapse or refractory after 3 or more       │
│ previous lines of chemotherapy (and/or HSCT)       │ previous lines of chemotherapy (and/or HSCT)       │
│ treatment                                          │ treatment                                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ AML or antecedent MDS secondary to prior           │ AML or antecedent MDS secondary to prior           │
│ chemotherapy                                       │ chemotherapy                                       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Persistent clinically significant non-             │ Persistent clinically significant non-             │
│ hematological toxicity that is Grade >1 by NCI     │ hematological toxicity that is Grade \>1 by NCI    │
│ CTCAE v4 from prior chemotherapy                   │ CTCAE v4 from prior chemotherapy                   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Patients who have had HSCT and are within 100 days │ Patients who have had HSCT and are within 100 days │
│ of transplant and/or are still taking              │ of transplant and/or are still taking              │
│ immunosuppressive drugs and/or have clinically     │ immunosuppressive drugs and/or have clinically     │
│ significant graft-versus-host disease requiring    │ significant graft-versus-host disease requiring    │
│ treatment and/or have >Grade 1 persistent non      │ treatment and/or have \>Grade 1 persistent non     │
│ hematological toxicity related to the transplant   │ hematological toxicity related to the transplant   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Clinically active central nervous system (CNS)     │ Clinically active central nervous system (CNS)     │
│ leukemia Patients with CNS leukemia which is       │ leukemia Patients with CNS leukemia which is       │
│ controlled but who are still receiving IT therapy  │ controlled but who are still receiving IT therapy  │
│ at study entry may be considered eligible and      │ at study entry may be considered eligible and      │
│ continue receive IT therapy at the discretion of   │ continue receive IT therapy at the discretion of   │
│ the Investigator and with agreement of the Sponsor │ the Investigator and with agreement of the Sponsor │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Patients who have previously received AC220        │ Patients who have previously received AC220        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Disseminated intravascular coagulation (DIC)       │ Disseminated intravascular coagulation (DIC)       │
│ (diagnosis by laboratory or clinical assessment)   │ (diagnosis by laboratory or clinical assessment)   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Major surgery within 4 weeks prior to enrollment   │ Major surgery within 4 weeks prior to enrollment   │
│ in the study                                       │ in the study                                       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Radiation therapy within 4 weeks prior to or       │ Radiation therapy within 4 weeks prior to or       │
│ concurrent with study                              │ concurrent with study                              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Uncontrolled or significant cardiovascular disease │ Uncontrolled or significant cardiovascular disease │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Women who are pregnant lactating or unwilling to   │ Women who are pregnant lactating or unwilling to   │
│ use contraception if of childbearing potential     │ use contraception if of childbearing potential     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Men who are unwilling to use contraception if      │ Men who are unwilling to use contraception if      │
│ their partners are of childbearing potential       │ their partners are of childbearing potential       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Active uncontrolled infection                      │ Active uncontrolled infection                      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Human immunodeficiency virus positivity            │ Human immunodeficiency virus positivity            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Active hepatitis B or C or other active liver      │ Active hepatitis B or C or other active liver      │
│ disease                                            │ disease                                            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of cancer except Stage 1 cervix or         │ History of cancer except Stage 1 cervix or         │
│ nonmelanotic skin cancer with the possible         │ nonmelanotic skin cancer with the possible         │
│ exception of patients in complete remission        │ exception of patients in complete remission        │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╛



╒═════════════════════════════════════════════════════════════════════════════════════════════════════╕
│ CHIA Criteria Not Found in Personal                                                                 │
╞═════════════════════════════════════════════════════════════════════════════════════════════════════╡
│ ECOG performance status of 0 to 2                                                                   │
├─────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Serum creatinine ≤1 5 × ULN and glomerular filtration rate (GFR) > 30 mL/min                        │
├─────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Use of concomitant drugs that prolong QT/QTc interval and/or are CYP3A4 inhibitors are prohibited   │
│ with the exception of antibiotics antifungals and other antimicrobials that are used as standard of │
│ care to prevent or treat infections and other such drugs that are considered absolutely essential   │
│ for the care of the patient                                                                         │
╘═════════════════════════════════════════════════════════════════════════════════════════════════════╛



╒═════════════════════════════════════════════════════════════════════════════════════════════════════╕
│ Extra Personal Criteria                                                                             │
╞═════════════════════════════════════════════════════════════════════════════════════════════════════╡
│ Eastern Cooperative Oncology Group performance status of 0 to 2                                     │
├─────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Must have maximum age of 85 Years                                                                   │
├─────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Serum creatinine ≤1 5 × upper limit of normal (ULN) and glomerular filtration rate (GFR) \> 30      │
│ mL/min                                                                                              │
├─────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Must have minimum age of 18 Years                                                                   │
├─────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Use of concomitant drugs that prolong the time between the start of the Q wave and the end of the T │
│ wave (QT)/corrected interval between the Q wave and T wave (QTc) interval and/or are CYP3A4         │
│ inhibitors are prohibited with the exception of antibiotics antifungals and other antimicrobials    │
│ that are used as standard of care to prevent or treat infections and other such drugs that are      │
│ considered absolutely essential for the care of the patient                                         │
╘═════════════════════════════════════════════════════════════════════════════════════════════════════╛